Mellaril was evaluated as treatment of behavior disorders in 100 epileptic patients in a study extending over a period of 3 to 10 months. Marked improvement in behavior was achieved in 61 patients and moderate improvement in another 28 patients.An unexpected consequence was the concomitant reduction in epileptic seizures, 64 of the 100 patients exhibiting no or fewer convulsive attacks during the administration of Mellaril. This provides tacit evidence that control of the emotional factors can exert a beneficial effect on seizures. However, it is emphasized that specific anticonvulsant medication was continued throughout the course of this study.Repeat examinations failed to reveal any signs of jaundice, photosensitivity, blood dyscrasia, extrapyramidal stimulation, or dermatitis.Abstract Teaser